- Home
- QURE vs DNTH Comparison
QURE vs DNTH Comparison
Compare QURE & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- DNTH
- Stock Information
- Founded
- QURE 1998
- DNTH 2015
- Country
- QURE Netherlands
- DNTH United States
- Employees
- QURE N/A
- DNTH N/A
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- QURE Health Care
- DNTH Health Care
- Exchange
- QURE Nasdaq
- DNTH Nasdaq
- Market Cap
- QURE 725.4M
- DNTH 606.2M
- IPO Year
- QURE 2007
- DNTH N/A
- Fundamental
- Price
- QURE $15.21
- DNTH $21.79
- Analyst Decision
- QURE Strong Buy
- DNTH Strong Buy
- Analyst Count
- QURE 10
- DNTH 8
- Target Price
- QURE $37.20
- DNTH $53.00
- AVG Volume (30 Days)
- QURE 1.0M
- DNTH 380.4K
- Earning Date
- QURE 07-29-2025
- DNTH 08-07-2025
- Dividend Yield
- QURE N/A
- DNTH N/A
- EPS Growth
- QURE N/A
- DNTH N/A
- EPS
- QURE N/A
- DNTH N/A
- Revenue
- QURE $20,201,000.00
- DNTH $6,524,000.00
- Revenue This Year
- QURE N/A
- DNTH N/A
- Revenue Next Year
- QURE $278.91
- DNTH N/A
- P/E Ratio
- QURE N/A
- DNTH N/A
- Revenue Growth
- QURE 6.30
- DNTH 102.36
- 52 Week Low
- QURE $4.45
- DNTH $13.37
- 52 Week High
- QURE $19.18
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- QURE 55.32
- DNTH 64.15
- Support Level
- QURE $13.61
- DNTH $19.90
- Resistance Level
- QURE $15.49
- DNTH $22.49
- Average True Range (ATR)
- QURE 0.81
- DNTH 1.46
- MACD
- QURE 0.08
- DNTH 0.25
- Stochastic Oscillator
- QURE 72.65
- DNTH 71.22
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.